1 The Argument for Oversight: Developments in the US John Steinbruner University of Maryland Controlling Dangerous Pathogens Project: Regional Workshop.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

THE NIH RECOMBINANT DNA 2002 GUIDELINES East Carolina University September 5, 2007.
Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
Principles of Standards and Measures
The Way Ahead How can we make a difference for good as a result of this meeting? What problems are we trying to solve? Laboratory Capacity? Clinical/Diagnostics,
BIOETHICS: THE SUBJECT, PURPOSE AND OBJECTIVES OF THE HEALTH CARE SYSTEM. BIOETHICS OF BIOMEDICAL EXPERIMENTS. INTERNATIONAL DOCUMENTS ON BIOETHICS AND.
Adapted from ISEF webpage Society for Science and the Public “Roles and Responsibilities of students and adults” Roles and Responsibilities of students.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Measuring Ethical Goals of Research Oversight Holly Taylor, PhD, MPH Department of Health Policy and Management Bloomberg School of Public Health Berman.
Outline Introduction to the National Institutes of Health Office of Biotechnology Activities History and Evolution of IBCs: Asilomar to the Present Overview.
Bioterrorism: Changing Priorities in Medical Training and Research Richard Coico Professor and Chairman Department of Microbiology & Immunology City University.
Brian J. Gorman, M.Sc., J.D. Towson University, Maryland Presentation for The National Academies’ Committee on Scientific Communication and National Security.
Awareness and Education About the BTWC Professor Malcolm Dando University of Bradford UK.
“The Life Sciences, Biosecurity, and Dual Use Research” Designed by: Brian Rappert Malcolm Dando University of Exeter Bradford University Marie Chevrier.
DUAL USE RESEARCH OF CONCERN US Government (USG) Policy for Institutional Oversight of Life Sciences 10/13/2014.
1 The Basic Problem: Dual-Use Research Kathryn Nixdorff Department of Microbiology and Genetics Darmstadt University of Technology, Germany.
Use of Children as Research Subjects What information should be provided for an FP7 ethical review?
The International Regulation of Biotechnology Lecture No. 19 Further Inf. For further information and video link please click on the right buttons in the.
Dual-Use: The Fink Report
The Select Agent Laboratory: at the intersection of research, preparedness and safety Nancy Connell,PhD Professor and Vice-chair for Research Department.
Draft Lecture No 14 By Malcolm Dando. I. Outline The concept of dual-use Slides The Fink Committee Report –A. Objective and structure of the report.
The International Regulation of Biotechnology Lecture No. 19.
The Growth of Dual-Use Bioethics Lecture No.13 Further Inf. For further information and video link please click on the right buttons in the following slides.
Overview of the Lectures in the Education Module Resource Lecture No. 1.
UK Office for Security & Counter Terrorism Future threats and the potential role of the CBRN Action plan in supporting the BTWC Dr Catherine Terry International.
Protection Against Occupational Exposure
Biosafety and recombinant DNA technology. Involves.... Experiments involving the construction or use of GMOs should be conducted after performing a biosafety.
Internal Auditing and Outsourcing
“Study on Other States’ Regulatory Oversight of Waste and Material Handling Activities Relative to Recycling Centers, Transfer Stations, and Green Material.
IAEA International Atomic Energy Agency International Cooperation in Nuclear Security David Ek Office of Nuclear Security.
NATIONAL CAPACITY FOR EVALUATION OF EVIDENCE AND DECISION-MAKING Mauro Toledo Marrelli Universidade de São Paulo.
RS–IAP-ICSU, September 2006 NSABB National Science Advisory Board on Biosecurity Dual Use Research: Scope, Criteria and Communication.
Knowing what you get for what you pay An introduction to cost effectiveness FETP India.
Local Recombinant DNA Oversight Mass Biotech Council Series Enforcement of the Cambridge Recombinant DNA Technology Ordinance Cambridge Biosafety Committee.
BSAF-BIONET Meeting Robert J. Hashimoto, CBSP University of California, Berkeley October 2, 2009.
Risk Assessment. Risk As defined by Kaplan and Garrick, risk analysis consists of answering three specific questions: what can happen? what is the chance.
Dual Use Research of Concern Boston University and Boston Medical Center.
Corporate Responsibility and Compliance A Resource for Health Care Boards of Directors By Debbie Troklus, CHC and Michael C. Hemsley, Esq.
XXX_DECRIPT_MON00/1 Quality and impact of Social Science and Operations Research by the Special Programme in Human Reproduction Department of Reproductive.
Excellence in science The Royal Society is the independent scientific academy of the UK dedicated to promoting excellence in science. Royal Society’s work.
Discuss the major characteristics of the four Biosafety Levels. Define “Risk Group” and give an example of each. Discuss how Risk Groups are used in conjunction.
Dual Use Research of Concern (DURC) University of North Carolina at Greensboro.
An International Conference that Examines the Issues of Yesterday, the Challenges of Today, and the Opportunities for Tomorrow SARS: Crisis and Opportunity.
Governor’s Taskforce for Pandemic Influenza Preparedness Issue Paper Credible and Effective Decision-making Workgroup Members Robert Rolfs, State Epidemiologist,
World Health Organization Life science research: opportunities and risks for public health Ottorino Cosivi Department of Epidemic and Pandemic Alert and.
SECTION IV: GENERAL DESCRIPTION OF STEPS TAKEN OR ENVISAGED BY NON-ANNEX I PARTY TO IMPLEMENT THE CONVENTION Workshop on the Use of the Guidelines for.
Use of Vaccines in a BVDV Control/Eradication Program Steven R. Bolin, DVM, PhD Diagnostic Center for Population & Animal Health Michigan State University.
1 EPIDEMIOLOGY 200B Methods II – Prediction and Validity Scott P. Layne, MD.
Controlling Dangerous Pathogens Elisa D. Harris Center for International and Security Studies at Maryland BWC Meeting of Experts Geneva, 19 August 2003.
Agencia Nacional de Evaluación de la Calidad y Acreditación Methods and approaches for a management and evaluation of research at the Higher Education.
Dual Use Research, Bioweapons and Biosecurity Iris Hunger Research Group for Biological Arms Control Carl Friedrich von Weizsäcker Centre for Science and.
Biotechnology / Life Sciences Ensuring Access Christina Sampogna July 2005 CASRIP – University of Washington, Seattle *Views expressed are those of the.
1 Program For Results Financing OP/BP 9.00 Agi Kiss WB Safeguards Training Workshop Almaty, December 2012.
Medical law and its place in the system of law and legislation in Ukraine. Legislative provision in healthcare in Ukraine.  The concept, object, method.
Royal Irish Academy Briefing Bert Rima 109/01/2016.
ASDPE International Health Regulations (IHR 2005) Laboratory and Zoonosis update Dr Richard Brown, WHO Thailand Workshop on Laboratory Diagnosis for Zoonotic.
DELEGATION DELEGATION Doing It Right Our Objectives To delegate patient care task safely & appropriately To understand laws & regulations affecting.
ERINHA: Framework for the biological high containment research infrastructure STOA – AVIESAN Workshop June 19th 2012, European Parliament, Brussels.
HPTN Ethics Guidance for Research: Community Obligations Africa Regional Working Group Meeting, May 19-23, 2003 Lusaka, Zambia.
Objectives  Define risk assessment as it relates to biosafety  Understand the risk assessment process and how to implement it  Discuss risk factors.
Ratification of BWC BWC Expert Group, Republic of Korea Compendium of National Activities in Korea: Measures to Improve Biosafety and Biosecurity Hei Chan.
NIH Guidelines for Research Involving rDNA Molecules (NIH Guidelines) and Institutional Biosafety Committees.
INFORMATION DISASTER PREPAREDNESS PLANNING (IDPP).
Dual Use Research of Concern
Stanford University Dual Use Research of Concern in the Life Sciences
An Overview on Risk Management
IIASA Governance Review
On Human Gene Editing: International Summit Statement
ADVAC ALUMNI MEETING DURING SAGE
Vascularized Composite Allograft (VCA) Transplantation Committee
Presentation transcript:

1 The Argument for Oversight: Developments in the US John Steinbruner University of Maryland Controlling Dangerous Pathogens Project: Regional Workshop on Dual-Use Research Matrahaza, Hungary May 12 – 14, 2006

2 Conception of the Fundamental Problem Rapid progress in basic molecular biology is apparently enabling extraordinarily consequential applications, including in principle deliberate intervention in the process of evolution. The same basic science simultaneously identifies both therapeutic and destructive possibilities. The extended consequences of this situation cannot be determined with confidence. Those consequences will assuredly involve social dynamics as well as basic science.

3 Recent reconstruction of the 1918 influenza virus is currently the leading instance of the more general problem. –Work actually motivated by “historical curiosity” but does have potentially important therapeutic implications. –Degree of oversight and containment applied does not appear commensurate with the magnitude of risk entailed. Reconstructed strain is substantially more virulent than standard reference strains. SARS has escaped BSL 3 containment at least 3 times. –Decision on publication made with no intermediate option available.

4 Evident Implications The scale and character of potential consequences mandate more advanced protective procedures than have yet been devised. In principle appropriate procedures should: –Prevent the deliberate or inadvertent creation of pathogens more destructive than those that have naturally evolved. –Assure prudent exploration of protective and therapeutic applications. –Assure equitable access to all constructive applications.

5 The Basic Principle of Protection Since the potential for constructive and destructive application of biotechnology cannot be categorically disentangled, effective protection depends on reinforcing and existing behavioral rule: Biotechnology must not be used to do deliberate harm under any circumstance for any reason Categorical rule must be adapted to specific context to be meaningfully applied.

6 That basic principle is reasonably well established as a universal norm. Has been authoritatively articulated: –The Hippocratic Oath. –The 1925 Geneva Protocol. –The 1972 Biological and Toxin Weapons Convention. Is broadly upheld and not expressly rejected. Nonetheless it must be substantially strengthened if it is to be the practical foundation for protection.

7 Recent Developments in the US Fink Committee report by US National Academy of Sciences: –Acknowledged the extraordinary consequence and inevitably associated danger of biotechnology. –Noted that current US regulatory procedures do not provide for independent review of the social consequences of fundamental research.

8 – Recommended extending current RAC review process to examine social consequences for 7 “experiments of concern,” ones that might: Render a vaccine ineffective. Confer antibiotic or antiviral drug resistance. Enhance the virulence of a pathogen. Increase the transmissibility of a pathogen. Alter the host range of a pathogen. Evade diagnostic detection. Enable weaponization.

9 –Noted that effective oversight measures would have to be global in scope. –Urged international discussion of that requirement especially within the scientific community.

10 Bush administration’s Biosecurity initiative established the National Science Advisory Board for Biosecurity (NSABB) to : –Develop guidelines for local and national oversight. –Develop code of conduct for scientists and lab workers. –Develop education and training programs. –Develop guidelines for dissemination of results. –Promote international extension.

11 Evident Problems Oversight procedures recommended by the Fink committee and projected by the NSABB: –Would not be comprehensive within the US – would not include commercial and biodefense research. –Would not be mandatory and therefore probably not adequately financed. –Would not apply beyond the US. –Offer no metric for dimensions of concern.

12 Surge of biodefense activity without provisions for assured transparency is likely to inspire intense suspicion and potentially dangerous reaction. > $ 1 billion annually for new research in the US in sensitive areas. Constructive discussion by the international community has become more urgent but is not yet organized.

13 Basic Requirements To provide maximum protection at acceptable cost an oversight process would have to be: –Global in scope of application – all parts of the world –Categorically inclusive – all relevant research activities. –Credibly focused. –Legally mandatory. –Actively practiced. –Efficiently organized. –Appropriately constrained.

14 An Illustrative Design An oversight process meeting those requirements might operate in three tiers: –International jurisdiction over research activities of extreme concern that might generate pathogens more lethal or otherwise more consequential than those currently extant in nature. –National jurisdiction over research activities of moderate concern – the more lethal of currently regulated agents. –Local jurisdiction over activities of potential concern involving agents that might be elevated to moderate or extreme categories by use of advanced manipulation techniques.

15 Using a conceptual definition of danger based on : –Spontaneous transmissibility = capacity to propagate between hosts under standard conditions. –Infectivity = capacity to penetrate a host and reproduce. –Pathogenicity = capacity to generate a lethal of otherwise hostile effect within an infected host.

16 Conceptual Parameters of Danger

17 Such an arrangement: –Would license relevant individuals and research facilities. –Would subject individual projects to prior review. –Would set conditions for the conduct of research and for the dissemination of results calibrated to the degree of danger involved. –Would initiate procedures of harmonizing the review judgments made in separate jurisdictions

18 Practical Implementation Criteria for determining oversight jurisdiction: –Activities of Extreme Concern (AEC): Any work on the variola virus (smallpox) or a comparably virulent agent that has been eradicated in nature, Any spontaneously infectious agent requiring BSL 4/ABSL 4 level of containment, De novo synthesis of any agent matching the above characteristics, Expanding the host range of an agent or changing the tissue range of an agent that would otherwise be assigned to a lower tier category, Constructing vaccine resistant or antibiotic resistant strains of agents that would otherwise be assigned to lower tier categories.

19 –Activities of Moderate Concern (AMC): Increasing virulence of listed agent or related agent. Insertion of host genes into listed agent or related agent. Increasing transmissibility or environmental stability of listed agent or related agent. Powder or aerosol production of listed agent or related agent. Powder or aerosol dispersal of listed agent or related agent. De novo synthesis of listed agent or related agent. Construction of antibiotic- or vaccine-resistant related agent. Genome transfer, genome replacement, or cellular reconstitution of listed agent or related agent.

20 –Activities of Potential Concern (APC): Work with listed agent— or exempt avirulent, attenuated, or vaccine strain of select agent — not covered by AEC/AMC. Increasing virulence of non-listed agent. Increasing transmissibility or environmental stability of non- listed agent. Powder or aerosol production of non-listed agent. Powder or aerosol dispersal of non-listed agent. De novo synthesis of non-listed agent. Genome transfer, genome replacement, or cellular reconstitution of non-listed agent

21 –A survey of US grant applications and research publications 2000 – 2005 indicates that under these criteria of jurisdiction a total of 310 research facilities and 2,574 individuals would have been subjected to oversight, of which: 12 facilities and 185 individuals would have been assigned to international oversight; 14 facilities and 133 individuals would have been assigned to national oversight. 231 facilities and 2,119 individuals would have been assigned to local oversight. 53 facilities and 137 individuals would have encountered multiple jurisdictions.

22 Criteria for risk-benefit assessment: –Biosafety Rating: whether proposed research plan minimizes risk to public and environment. –Adequacy of Research Plan: whether there are scientific reasons why same outcome cannot be pursued through other means. –Public health rationale: whether research will advance understanding of disease causing properties of existing pathogens. –Biodefense rationale: whether work being done in response to validated or theoretical threat. –Current necessity of work: whether there are medical countermeasures available for use against agents to be constructed. –Potential impact: whether proposed results will inform policy

23 Current State of the Problem Momentum of the research process is continuously generating highly consequential lines of inquiry. Immediate terrorist threat is comparable to or less than the natural incidence of infectious disease –and can be addressed by enhanced public health measures. Hostile competition among national threat assessment programs is a more serious immediate concern than potential terrorism. Exclusive subordination of national threat assessment activities to public health jurisdiction and application of transparency rules are urgent priorities.